Compare SUNS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | SCYX |
|---|---|---|
| Founded | 2023 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 32.6M |
| IPO Year | N/A | 2014 |
| Metric | SUNS | SCYX |
|---|---|---|
| Price | $8.32 | $0.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $8.75 | $3.00 |
| AVG Volume (30 Days) | 78.6K | ★ 318.1K |
| Earning Date | 03-12-2026 | 03-04-2026 |
| Dividend Yield | ★ 14.44% | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | $110.86 | $90.24 |
| Revenue Next Year | $9.41 | N/A |
| P/E Ratio | $8.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.80 | $0.57 |
| 52 Week High | $11.78 | $1.29 |
| Indicator | SUNS | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 29.07 | 61.59 |
| Support Level | N/A | $0.68 |
| Resistance Level | $9.69 | $1.29 |
| Average True Range (ATR) | 0.28 | 0.06 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 1.69 | 73.68 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.